Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

Nektar Therapeutics (NKTR)

82 Posts, Pagina: « 1 2 3 4 5 » | Laatste

Omlaag ↓

[verwijderd] 31 januari 2006 15:00

finance.yahoo.com/q/bc?s=NKTR&t=1y

Het is maar hoe je het bekijkt. Heeft al vaker tegen de 20 gestaan, terwijl er toen nog heel veel onzekerheid was over goedkeuring. Nu is het er en verwacht pfizer er heel veel van en koopt een andere partner in dit geheel uit voor 1.3 miljard.

[verwijderd] 31 januari 2006 15:20

NKTR:

Estimate Change; EXUBERA Approved; Silver Lining With a Cloud
EXUBERA approved with lung function recommendation
On Friday, the FDA approved Pfizer (PFE)/NKTR’s EXUBERA for diabetes. The
indications (combination with long acting insulin for type 1; monotherapy,
combination with oral agents/long acting insulin for type 2) are consistent with our
expectations. On a cumbersome note, the label recommends lung function tests at
the start of therapy and every 6-12 months thereafter. Discussions with primary
care physicians (PCPs) suggests that spirometers are easy to learn and use, but are
not commonly found in primary care settings. Hence, EXUBERA’s launch could be
tempered as PFE embarks on the education of PCPs on the use of spirometers.
EXUBERA estimates revised lower
Despite the positive outcome, NKTR stock could pull back following the exit of
momentum investors, and as others assess the impact of lung function tests. Our
EXUBERA estimates have been lowered due to this issue, and the staggered launches
resulting from reimbursement outcomes. Our end-user sales estimates have been
revised to $1 bn from $1.2 bn in 2009 (Please see Table 1). We remain positive on
NKTR based on pending royalties from EXUBERA, especially in the event of a pull
back.
BUY rating unchanged ( ''''''Buy)
Key milestones in 2006 include details of EXUBERA pricing, details regarding
marketing and pre-launch activities at PFE’s investor day (February 10), progress
on reimbursement, and data disclosure at major medical conferences.
Hari Sambasivam >>

[verwijderd] 31 januari 2006 15:20

10 februari dus meer informatie

[verwijderd] 31 januari 2006 16:47

boven de 20! Nu nog er boven sluiten en dan is de trend gezet.

[verwijderd] 31 januari 2006 16:56

20.40, klein short squeezje!

[verwijderd] 31 januari 2006 17:05

quote:
JaySS schreef:
Ik snap er dus niets meer van !!! Maar ik heb maar flink bijgekocht op 19.30 - 19.40. Ik geloof er helemnaal niets van !!!

Jay

Ik geloof er nog steeds niets van ! Heb er genoeg bijgekocht onder de 20, want dit is geen niveau waar we op blijven steken. Neerwaartse risico blijft zeeeeer beperkt.

Jay

[verwijderd] 1 februari 2006 00:04

Ik snap het ook niet. Goed nieuws met een dalende koers. Nou ja, voor de lange(re) termijn zie ik alleen maar groei, dus voorlopig houd ik ze gewoon aan.

[verwijderd] 2 februari 2006 09:32

SAN CARLOS, Calif.--(BUSINESS WIRE)--Feb. 1, 2006--Nektar Therapeutics (Nasdaq:NKTR - News) announced today that its corporate presentation will be webcast live from the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference, Wednesday, February 8, 2006 beginning at 9:20 a.m. Eastern Standard Time. The audio-only presentation may be accessed on Nektar's Investor Relations' page at www.nektar.com and will be available within 24 hours following the live presentation until February 15, 2006.

Nektar Therapeutics develops and enables high-value, differentiated therapeutics with its industry-leading drug delivery technologies, expertise and manufacturing capabilities. The world's top biotechnology and pharmaceutical companies are developing new and better therapeutics using Nektar's advanced technologies and know-how. Nektar also develops its own products by applying its drug delivery technologies and its expertise to existing medicines to enhance performance, such as improving efficacy, safety and compliance.

[verwijderd] 2 februari 2006 15:39

Nu te koop

optie NKTR feb 22,5 aan 0,15 cent...

[verwijderd] 8 februari 2006 13:28

Toch binnenkort een overname?

Nektar CEO to Retire
Tuesday February 7, 4:30 pm ET
Executive Chairman Appointed Acting CEO

SAN CARLOS, Calif.--(BUSINESS WIRE)--Feb. 7, 2006--Nektar Therapeutics (Nasdaq:NKTR - News) announced today that Ajit S. Gill will be retiring as CEO, President, and Director as of March 17, 2006. Robert Chess, Nektar's current Executive Chairman and former CEO, will serve as acting CEO on an interim basis after March 17 until a new CEO is found. Mr. Gill will serve as an advisor to the company after his retirement.

Mr. Gill said, "I have been privileged to work at Nektar since 1992 and to lead the company as Co-CEO since 1999 and CEO since April 2000. The company has grown tremendously during this time and several products with Nektar-developed technologies are improving the lives of patients. With the approval of Exubera® (inhaled insulin) by the Food and Drug Administration and the European Commission and the initiation of our proprietary products programs, I believe the company is well positioned for long-term success. Therefore it is an appropriate time to bring in a new CEO to lead Nektar in its next phase of growth to a more products focused drug delivery company."

"Ajit has done a terrific job in transitioning Nektar from an early stage, single platform company to one with a broad product line, multiple technologies, and a potential blockbuster product that has just gained approval," said Mr. Chess. "Ajit's business acumen, strategic vision, integrity and fairness have been integral to the success of the company and set a high standard for all of us at Nektar. He has assembled an outstanding team that will serve as his legacy for many years to come. I personally have greatly enjoyed working with Ajit over the last 14 years and am grateful for his enormous contributions to building our company."

Robert Chess joined Nektar in 1991, when the company was still known as Inhale Therapeutic Systems, as its first non-founder employee. He served as its CEO and then co-CEO until 2000, when he became Executive Chairman.

The Nektar Board of Directors has formed a CEO search committee that will be headed by Mr. Chess.

Nektar Therapeutics develops and enables high-value, differentiated therapeutics with its industry-leading drug delivery technologies, expertise and manufacturing capabilities. The world's top biotechnology and pharmaceutical companies are developing new and better therapeutics using Nektar's advanced technologies and know-how. Nektar also develops its own products by applying its drug delivery technologies and its expertise to existing medicines to enhance performance, such as improving efficacy, safety and compliance.

[verwijderd] 16 februari 2006 18:11

Vandaag weer een plusje van 2%. De laatste dagen hebben toch wel een herstel laten zien, ondanks dat in mijn ogen de echte klap nog zeker niet is gemaakt.

[verwijderd] 10 maart 2006 19:12

Nektar still far from the land of milk and honey

08/03/2006 - Its upcoming inhalable insulin drug may prove a blockbuster but Nektar’s 2005 results brought the biopharmaceutical company further in the red, with a net loss of $108.2m (€91m) in Q4 more than five times higher than the $19.3m loss it posted in Q4 of 2004, as it struggles not just with one-time charges but also with higher expenditure.

Hitting Nektar hardest were $65.3m in asset impairment related to Nectar UK, formerly Bradford Particle Design and acquired by Nektar in 2001, and $7.9m in purchased in-process research and development expenses associated with the acquisition of Aerogen, a drug delivery specialist.
However, even without these one-off items the company would have posted a net loss of $35m, $15.7m more than the $19.3m it lost in the Q4 of the previous year.
This was not down to decreased revenue; this came in at $32.9m compared to $31.4m year-on-year as the $5m Nektar got from Pfizer, for the preparation for commercial manufacture of its eagerly anticipated insulin drug Exubera, more than offset the $3.1m decline in contract research revenue, due to the fact that Exubera is ready for commercialisation, and the $300,000 drop in product and royalty revenue.
Where the company's bottom line suffered was in R&D costs, up $8.3m because of Nektar's focus on its proprietary drugs, general and administrative costs, up $4.9m as the firm increased its head count, and $4.2m in commercialization readiness costs for Exubera.
Whether the company's investment in proprietary drugs will pay off remains to be seen since Nektar's own drug furthest ahead in the pipeline is still in phase I; its amphotericin B inhalation powder for the prevention of lung fungal infections could help 200,000 patients in the US and Europe in a $400m market.
Nevertheless, newly acquired Aerogen does have a proprietary drug in phase II – amikacin, an inhaled antibiotic for the treatment of gram negative pneumonias in patients on mechanical ventilation.
Nektar UK's time on the other hand may soon be up as company spokeswoman Jennifer Ruddock hinted to In-PharmaTechnologist.com that, following the losses it caused to the company, 2006 will be a crunch year for the division, which supports activities ranging from laboratory evaluations to supply manufacturing.
“So far we have found Nektar UK to be an asset to our business but we will look at some clinical trials that come out of it later in the year and consider if it has value that we wish to unlock,” she said.
“After Exubera we are concentrating on proprietary drugs in specialty markets where short development times and low costs allow us to do so.”
Yet Nektar is also continuing to seek partnerships to benefit from its expertise in advanced pulmonary delivery, PEGylation and supercritical fluids.
In 2005 it struck deals with Bayer Healthcare, for inhaled ciprofloxacin for lung infections in cystic fibrosis patients, Baxter, who is using Nektar's PEGylation technology to develop longer-acting forms of blood clotting proteins for hemophiliacs,and Zelos Therapeutics, to create an inhaleable powder form of their parathyroid hormone analogue that is under development for osteoporosis patients.
What is more, two drugs licensed with Nektar's technology, Roche's CERA for renal anemia and UCB's Cimzia for Crohn's disease, are both in Phase III trials and are expected to be filed for approval by the end of 2006.
Then of course there is Exubera, approved in the US and the EU and scheduled to be distributed by Pfizer by mid-2006, providing manufacturing and royalty revenue in 2006 in the range of $60m to $80m, Nektar estimates.

[verwijderd] 11 maart 2006 12:10

Begrijp dat de royalties 8- 12 % zijn voor NKTR.
Zag vanmorgen andere schattingen voor Exubera:
1. Reddoch of Friedman/Bilings/Ramsey estimates the sales for Exubera at $ 2 billion in 2010.

en zeer (overdreven ??) optimistisch was:
2. Andrew Forman of WR Hambrecht expects the sales of Exubera to a a "conservative" $ 15 billion per year for the US and $ 20 billion worldwide.

NB Heb geen NKTR, zag die info op IBD.

quote:
Schouterman schreef:
....Then of course there is Exubera, approved in the US and the EU and scheduled to be distributed by Pfizer by mid-2006, providing manufacturing and royalty revenue in 2006 in the range of $60m to $80m, Nektar estimates.....

[verwijderd] 22 mei 2006 15:27

Nektar gets fast-track for anti-fungal drug
Mon May 22, 2006 8:50 AM ET
CHICAGO, May 22 (Reuters) - Nektar Therapeutics (NKTR.O: Quote, Profile, Research) on Monday said U.S. regulators granted a fast-track review for its Amphotericin B inhaled drug to prevent fungal infections in patients at risk because of organ transplants or leukemia treatment.

Fast-track designation by the Food and Drug Administration is designed to speed the review of new drugs intended to treat serious or life-threatening conditions and that show the potential to address unmet medical needs.

[verwijderd] 28 september 2006 15:52

09/28/2006 13:34 Nektar Therapeutics upgraded by Miller Johnson (Briefing.com)

finance.yahoo.com/q/ud?s=NKTR

[verwijderd] 3 november 2006 15:20

Nektar Therapeutics Narrows 3Q Loss
Thursday November 2, 5:25 pm ET
Nektar Therapeutics Narrows 3Q Loss As Revenue Grows; Company Raises Full-Year Forecast

SAN CARLOS, Calif. (AP) -- Biopharmaceutical company Nektar Therapeutics said Thursday its third-quarter loss narrowed as revenue from product sales and royalty payments surged.

The company lost $19.6 million, or 22 cents per share, compared with $23.8 million, or 28 cents per share, a year ago.

ADVERTISEMENT
Analysts polled by Thomson Financial expected a loss of 37 cents per share.

Excluding $2.9 million in charges for stock-based compensation and $2.7 million in severance and restructuring charges, the company's loss was $14 million, or 16 cents per share.

Revenue surged to $58.6 million from $36.4 million a year ago. Analysts expected revenue of $51.3 million.

Contract research revenue shrunk to $15.1 million from $23.7 million, while product revenue jumped to $41.5 million from $8.5 million.

For the full year, Nektar expects a loss of between $95 million and $110 million, excluding charges, on revenue between $190 million to $210 million. Previously, Nektar expected a loss of $100 million to $115 million on revenue of $170 million to $200 million.

Analysts expect a loss of $124.7 million, excluding charges, on revenue of $193.2 million.

Shares of Nektar rose 5 cents to close at $14.01 on the Nasdaq. In aftermarket activity, they added another 49 cents, or 3.5 percent, to $14.50. The stock has ranged between $12.71 and $23.20 over the past year.

DeZwarteRidder 12 augustus 2019 13:24

Mizuho Lowers Nektar Therapeutics (NASDAQ:NKTR) Price Target to $79.00

Posted by Rob Hiaasen on Aug 12th, 2019

Nektar Therapeutics logoNektar Therapeutics (NASDAQ:NKTR) had its price objective lowered by research analysts at Mizuho from $81.00 to $79.00 in a research note issued to investors on Friday, July 26th, BenzingaRatingsTable reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 277.63% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. BidaskClub cut shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 16th. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a research report on Friday, June 14th. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Cowen set a $82.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 13th. Finally, ValuEngine upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $50.33.
Get Nektar Therapeutics alerts:

Shares of Nektar Therapeutics stock opened at $20.92 on Friday. The firm has a market cap of $5.15 billion, a PE ratio of 5.53 and a beta of 2.67. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The stock’s 50-day moving average price is $32.57. Nektar Therapeutics has a 12-month low of $17.50 and a 12-month high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. The business had revenue of $23.32 million during the quarter, compared to analysts’ expectations of $26.65 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 24.67%. The firm’s revenue for the quarter was down 97.9% on a year-over-year basis. During the same quarter last year, the company posted $5.33 EPS. On average, equities analysts predict that Nektar Therapeutics will post -3.13 EPS for the current year.

DeZwarteRidder 12 augustus 2019 13:24

In other news, SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $108,571.57. Following the completion of the sale, the senior vice president now owns 95,913 shares in the company, valued at approximately $3,008,790.81. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Gil M. Labrucherie sold 3,767 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $118,170.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 253,283 shares of company stock valued at $8,356,254. 4.02% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. grew its stake in Nektar Therapeutics by 54.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 6,761 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 2,395 shares during the period. Advisor Group Inc. grew its stake in Nektar Therapeutics by 21.4% in the 4th quarter. Advisor Group Inc. now owns 6,638 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 1,168 shares during the period. Dimensional Fund Advisors LP grew its stake in Nektar Therapeutics by 82.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 408,526 shares of the biopharmaceutical company’s stock worth $13,433,000 after acquiring an additional 184,055 shares during the period. Principal Financial Group Inc. grew its stake in shares of Nektar Therapeutics by 0.9% during the 4th quarter. Principal Financial Group Inc. now owns 288,227 shares of the biopharmaceutical company’s stock valued at $9,474,000 after buying an additional 2,637 shares during the period. Finally, Metropolitan Life Insurance Co. NY grew its stake in shares of Nektar Therapeutics by 1.2% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 32,910 shares of the biopharmaceutical company’s stock valued at $1,082,000 after buying an additional 401 shares during the period. Institutional investors own 92.09% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

DeZwarteRidder 13 augustus 2019 07:37

Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues
Nektar dropped 40% on Friday after announcing it had manufacturing issues in two batches of experimental cancer drugs.
Tony Owusu
Aug 12, 2019 1:30 PM EDT
Nektar Therapeutics Pharmaceutical company

Shares of Nektar Therapeutics (NKTR - Get Report) were down nearly 10% Monday, following on from a 40% decline on Friday as investors digested the company's announcement that its experimental cancer drug study ran into some issues.

Last week, the company announced that it had manufacturing issues in two batches of experimental cancer drugs that the company gave to patients in a trial.

Those two batches resulted in treatment responses that weren't as optimistic as expected, leading analysts at J.P. Morgan, Jefferies and Mizuho Securities to downgrade the stock to hold.

"Nektar is making good progress advancing our multiple programs in immuno-oncology, immunology and pain," said Howard W. Robin, president and CEO of Nektar. "With our partner Bristol-Myers Squibb, although we've experienced some delays, we are working to finalize the development program for bempegaldesleukin in combination with nivolumab in a number of tumor types and which are designed to support registration for this unique I-O doublet."

Separately, the company recently reported a quarterly loss of 63 cents a share on revenue of $23.3 million. Analysts were expecting a loss of 80 cents a share on revenue of $26.6 million.

Nektar shares fell 9.7% to $18.90 on Monday.

DeZwarteRidder 13 augustus 2019 17:49

About Bempegaldesleukin (NKTR-214), Nektar's Lead Immuno-oncology Candidate

Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient's own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these effector T cells.1 In clinical and preclinical studies, treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment.2,3 Bempegaldesleukin has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

A Phase 1 study evaluating bempegaldesleukin as a single agent in patients with locally recurrent or metastatic solid tumors including melanoma, renal cell carcinoma (RCC), bladder, colorectal and other solid tumors is complete. Results from this First-in-Human trial were published in Cancer Discovery and showed encouraging evidence of anti-tumor activity, and a favorable safety and tolerability profile. (Cancer Discov 2019;9:1–11)

In February 2018, Nektar and Bristol-Myers Squibb entered into a global development and commercialization agreement to evaluate the full potential of bempegaldesleukin plus Opdivo® (nivolumab) in more than 20 indications in 9 tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, bladder and triple negative breast cancer.

In November 2018, Nektar announced a clinical collaboration with Pfizer to evaluate bempegaldesleukin in combination with avelumab and talazoparib or enzalutamide in multiple cancer settings including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).

Additional development plans for bempegaldesleukin include combination studies with additional checkpoint inhibitors, cell therapies and vaccines.
About the Phase 3, Randomized, Open-label Study of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma

The Phase 3 study will test the effectiveness (how well the drug works), safety, and tolerability of bempegaldesleukin, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread. For more information, please visit clinicaltrials.gov and search NCT03635983.

About the Phase 3, Randomized, Open-label Study to
Compare Bempegaldesleukin Combined With Nivolumab to the
Investigator's Choice of Sunitinib or Cabozantinib in
Patients With Previously Untreated Advanced Renal
Cell Carcinoma

The Phase 3 study will compare the overall response rate (ORR) and overall survival (OS) of
bempegaldesleukin combined with nivolumab to that of a tyrosine kinase inhibitor (TKI)
monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with
previously untreated advanced renal cell carcinoma (RCC). For more information, please
visit clinicaltrials.gov and search NCT03729245.

82 Posts, Pagina: « 1 2 3 4 5 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	914,65	+1,40	+0,15%	17:17
AMX	955,00	+1,91	+0,20%	17:17
ASCX	1.224,26	-0,34	-0,03%	17:02
BEL 20	4.002,48	-2,32	-0,06%	17:17
Germany40^	18.767,80	+63,38	+0,34%	17:17
US30^	40.049,90	+54,80	+0,14%	17:17
US500^	5.321,23	+18,75	+0,35%	17:17
Nasd100^	18.656,90	+116,70	+0,63%	17:17
Japan225^	39.192,40	+460,40	+1,19%	17:16
WTI	79,43	-0,08	-0,10%	17:17
Brent	83,74	-0,13	-0,16%	17:17
EUR/USD	1,0863	-0,0006	-0,06%	17:17
BTC/USD	67.198,49	+374,72	+0,56%	17:17
Gold spot	2.425,05	+9,84	+0,41%	17:17